Medicinal cannabis

Understanding the Medical Chemistry of the Cannabis Plant is Critical to Guiding Real World Clinical Evidence

“…It is thus hoped that in addition to receptor activities, the inclusion of biomarkers and clinical markers such as cytokine levels and von Frey filament measurements as dependent variables could lead to more sophisticated modeling that accurately elucidates the relationship(s) between the chemical makeup of medical cannabis and their corresponding in-vivo clinical outcomes for ailments such as inflammation and chronic pain. Presently, healthcare professionals play an auxiliary role in the administration of medical cannabis, which is largely self-titrated by patients [ 53 , 54 ]. As such, more advanced and clinically relevant models could serve to guide physicians in their medical cannabis prescriptions, by narrowing down potential effective chemovars based on the type and severity of symptoms experienced by patients.…”

Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors

“…Cannabinoids primarily interact with cannabinoid receptor types 1 and 2 (CB1 and CB2, respectively), but they can also interact with other receptors such as serotonin receptors and vanilloid-type transient receptor potential (TRPV) channels, which result in the physiological effects of cannabis, including psychoactivity or euphoria, motor impairment, analgesia, and immunomodulation [4][5][6]. The medicinal properties of cannabis and its derivative products make them potential treatments for managing the symptoms of several neurological and psychiatric disorders; they are also increasingly popular alternatives to opioids and are used by patients suffering from nausea, epilepsy, neuropathic pain, and post-traumatic stress disorder (PTSD) [7][8][9]. In most jurisdictions around the world, medical cannabis is accessible to patients, although it does not possess a drug identification number or a similar authorization by relevant drug control authorities [10,11].…”

“…Here, through a series of experiments comprising chemical extractions, quantitative analyses, and CB1/CB2 receptor activity profiling, we have undertaken a comprehensive investigation of 59 cannabis samples, their chemical compositions, and receptor activities and identified if there are any The medicinal properties of cannabis and its derivative products make them potential treatments for managing the symptoms of several neurological and psychiatric disorders; they are also increasingly popular alternatives to opioids and are used by patients suffering from nausea, epilepsy, neuropathic pain, and post-traumatic stress disorder (PTSD) [7][8][9]. In most jurisdictions around the world, medical cannabis is accessible to patients, although it does not possess a drug identification number or a similar authorization by relevant drug control authorities [10,11].…”

“…The composition of phytocannabinoids in these cannabis varieties can vary significantly, leading to a range of biological and physiological responses; for example, the ∆ 9 -THC content in cannabis samples can range from 0.14% to more than 25%, and, depending on the concentration of other phytocannabinoids, the resulting biological activities vary [12]. Interestingly, the variety (based on chemical composition), dose, and the route of administration of medical cannabis are largely determined by patients through self-titration with healthcare professionals playing an advisory role [7,11]. In fact, there have been no systematic studies investigating the relationship between the chemical constituents of different medical cannabis varieties and their corresponding combined therapeutic effects and receptor activities.…”